• Home
  •  / Michelson Diagnostics

Michelson Diagnostics

  • Revenue£630.2 KFY, 2015
  • Total Funding$10.8 M

OverviewSuggest Edit

Michelson Diagnostics is the developer and manufacturer of products based on Multi-Beam Optical Coherence Tomography(OCT), the uniquely powerful, innovative optical imaging technology that is capable of imaging living tissue microstructure at < 10 µm resolution, in real time, to depths of 1 mm or more.
Our breakthrough technology enables in-vivo capture, visualization and measurement of biological details that are too small to be seen with ultrasound, and too deep for conventional microscopy.

TypePrivate
Founded2006
HQMaidstone, GBMap
Websitevivosight.com
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Jul 2022)10
Revenue (FY, 2015)£630.2 K(-49%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Michelson Diagnostics

Jon Holmes

Jon Holmes

CEO
Martin Johns

Martin Johns

Operations Director
Show more

Michelson Diagnostics Office Locations

Michelson Diagnostics has offices in Maidstone and Atascadero
Maidstone, GB (HQ)
Eclipse House Sittingbourne Rd
Atascadero, CA, US
5444 Santa Fe Rd
Show all (2)

Michelson Diagnostics Financials and Metrics

Summary Metrics

Founding Date

2006

Michelson Diagnostics total Funding

$10.8 m

Michelson Diagnostics latest funding size

$2.85 m

Time since last funding

7 years ago

Michelson Diagnostics investors

Octopus Investments, London Business Angels, Octopus Ventures, Smith & Nephew, Catapult Ventures
Michelson Diagnostics's latest funding round in February 2015 was reported to be $2.9 m. In total, Michelson Diagnostics has raised $10.8 m
Show all financial metrics

Michelson Diagnostics Revenue

Embed Graph
View revenue for all periods
Michelson Diagnostics's revenue was reported to be £630.22 k in FY, 2015 which is a 49.6% decrease from the previous period.
GBP

Revenue (FY, 2015)

630.2k

Revenue growth (FY, 2014 - FY, 2015), %

(49.6%)

Gross profit (FY, 2015)

282.7k

Gross profit margin (FY, 2015), %

44.9%

Net income (FY, 2015)

(2.5m)

EBITDA (FY, 2015)

(2.5m)

EBIT (FY, 2015)

(2.7m)

Cash (30-Sept-2018)

610.8k
GBPFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015

Revenue

250.8k401.0k662.9k1.3m630.2k

Revenue growth, %

(50%)

Cost of goods sold

133.9k125.3k128.6k212.9k347.6k

Gross profit

116.9k275.7k534.2k1.0m282.7k
show all
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

144.9k365.9k606.2k393.2k1.4m2.0m254.4k393.7k1.4m182.0k143.3k610.8k

Accounts Receivable

42.3k74.2k135.2k83.9k6.1k31.0k27.3k202.2k33.5k4.7k154.6k50.3k

Inventories

62.6k78.0k232.4k138.1k272.5k164.0k488.1k556.6k565.0k515.4k270.1k

Current Assets

187.2k585.1k982.7k709.6k1.6m2.4m642.4k1.8m2.8m1.2m1.1m1.5m
show all
GBPFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015

Net Income

(745.3k)(1.4m)(2.1m)(1.8m)(2.5m)

Cash From Operating Activities

(697.3k)(1.6m)(1.7m)(1.9m)(2.0m)

Cash From Financing Activities

1.9m2.4m2.2m3.6m

Net Change in Cash

1.0m562.6k(1.7m)139.3k998.8k
show all
GBPFY, 2007

Financial Leverage

1.2 x
Show all financial metrics

Michelson Diagnostics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

80/100

Learn more about our premium products
SecurityScorecard logo

Michelson Diagnostics Online and Social Media Presence

Michelson Diagnostics's Trends

Embed Graph

Michelson Diagnostics News and Updates

May 27, 2022

Worldwide Dermatology Diagnostic Devices Industry to 2027 - Featuring Abbott Diagnostics, Strata Skin Sciences and Michelson Diagnostics Among Others

DUBLIN, May 27, 2022 /PRNewswire/ -- The "Dermatology Diagnostic Devices Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering. The global dermatology diagnostic devices market reached a value of...

Michelson Diagnostics Blogs

September 22, 2021

Sept 2021

Join us for our Sept 2021 issue of VivoScene!: • Latest News: Video Blog by MDL CEO Jon Holmes on recent Markowitz et al. paper: 98% Clearance at 1 Year withNonsurgical In-office Treatment of Basal Cell Carcinoma(BCC). • Feature: Merete Haedersdal, MD, PhD - On a Mission to Accelerate Discoveries an…
September 14, 2021

OCT-Guided Laser Treatment of Basal Cell Carcinoma

Video Blog: Jon Holmes, MA FInstP, FASLMS CEO - Michelson Diagnostics Ltd., Maidstone - UK OCT-Guided Laser Treatment of Basal Cell Carcinoma Jon Holmes, CEO of MDL, comments on a recent article by Orit Markowitz, MD et al. reporting positive results The post OCT-Guided Laser Treatment of Basal Cell…
June 09, 2021

AI Specialists Manchester Imaging Win UK Innovation Scholars Grant to Develop AI-enhanced Skin Cancer Detection Capability for Michelson Diagnostics’ VivoSight OCT Scanner

AI Specialists Manchester Imaging Win UK Innovation Scholars Grant to Develop AI-enhanced Skin Cancer Detection Capability for Michelson Diagnostics’ VivoSight OCT Scanner Click here to read the full press release. The post AI Specialists Manchester Imaging Win UK Innovation Scholars Grant to Develo…
December 14, 2020

Michelson Diagnostics teams up with AI Specialists Manchester Imaging to develop Machine Learning Algorithms for VivoSight OCT Skin Imaging System

Michelson Diagnostics teams up with AI Specialists Manchester Imaging to develop Machine Learning Algorithms for VivoSight OCT Skin Imaging System Click here to read the full press release. The post Michelson Diagnostics teams up with AI Specialists Manchester Imaging to develop Machine Learning Alg…
December 07, 2020

Measuring Skin with VivoSight OCT – Part 1: Epidermal Measurements

Video Blog: Jon Holmes, MSc CEO - Michelson Diagnostics Ltd., Maidstone - UK Part 1: Epidermal Measurements Join us for a multi-part video blog series with one of the preeminent experts in the field of dermatologic imaging. Jon Holmes covers aspects of Measuring skin with VivoSight OCT in an educati…
June 18, 2019

New Hope for Port Wine Stain Patients from a Novel Image-Guided Treatment

The post New Hope for Port Wine Stain Patients from a Novel Image-Guided Treatment appeared first on Vivosight.
Show more

 Michelson Diagnostics Frequently Asked Questions

  • When was Michelson Diagnostics founded?

    Michelson Diagnostics was founded in 2006.

  • Who are Michelson Diagnostics key executives?

    Michelson Diagnostics's key executives are Jon Holmes and Martin Johns.

  • How many employees does Michelson Diagnostics have?

    Michelson Diagnostics has 10 employees.

  • What is Michelson Diagnostics revenue?

    Latest Michelson Diagnostics annual revenue is £630.2 k.

  • What is Michelson Diagnostics revenue per employee?

    Latest Michelson Diagnostics revenue per employee is £63 k.

  • Who are Michelson Diagnostics competitors?

    Competitors of Michelson Diagnostics include LaVision BioTec, Trice Medical and Magnetic Insight.

  • Where is Michelson Diagnostics headquarters?

    Michelson Diagnostics headquarters is located at Eclipse House Sittingbourne Rd, Maidstone.

  • Where are Michelson Diagnostics offices?

    Michelson Diagnostics has offices in Maidstone and Atascadero.

  • How many offices does Michelson Diagnostics have?

    Michelson Diagnostics has 2 offices.